News & Views
Telix invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an…
Read more
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx…
Read more
Telix today announces new Director appointments as part of a Board succession planning and renewal…
Read more
Telix announces that the Biogenix Molecular Research Center in Miami, FL, is recruiting and dosing patients in the ProstACT Global Phase 3 trial of TLX591 for patients with advanced prostate…
Read more
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by ALMPS for the detection and…
Read more
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by MMA for the detection and…
Read more
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by NOMA for the detection and…
Read more
Telix today announces its financial results for the year ended 31 December…
Read more
Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix®…
Read more
Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix®…
Read more